- Joined
- Nov 16, 2017
- Messages
- 68
- Reaction score
- 10
CMS states the G2211 code modifier can be applied to “ongoing medical care related to a patient’s single, serious condition, or complex condition,” and that “G2211 captures the inherent complexity of the visit that’s derived from the longitudinal nature of the practitioner and patient relationship.”
While this is great, I am grappling with some grey areas. I just wanted to get the opinion of the members here as to what you think would be appropriate to apply the G2211 modifier.
Would you agree with my YES/NO in these scenarios below?
A) Metastatic malignancy currently on active induction chemo or immunotherapy or maintenance systemic therapy - YES
B) Metastatic malignancy, completed a period of treatment, currently on clinical/imaging surveillance - YES
C) Early stage cancer on chemotherapy or endocrine therapy - YES
D) Malignancy on targeted therapy - YES
E) MGUS - YES OR NO? - I am seeing them every 3-6 months, so this is ongoing care, but is this serious/complex? What would you do?
F) Iron deficiency anemia, has required parenteral iron a couple of times, being assessed every 6 months with labs to see if they are iron deficient and require PO/parenteral iron - YES? Or NO? If NO, if I am also commenting on their blood pressure or if they have a history of B12 deficiency that is now corrected - would this sway you toward YES?
G) Breast cancer diagnosed 6 years ago - completed 5 years of endocrine therapy - now on annual mammograms and exam and labs - YES or NO? Probably NO? But I am still seeing them long-term yearly, would this qualify for a YES?
H) History of DVT/PE, on apixaban or rivaroxaban, but only seeing them every 6 months or 1 year - YES or NO?
I) ITP patient not on treatment being followed with labs every 3 months - NO maybe?
I am having a bit of a hard time with what I perceive are grey areas in some of the scenarios above. Your opinion or a discussion on these would be quite helpful for us all, I think. Thank you.
While this is great, I am grappling with some grey areas. I just wanted to get the opinion of the members here as to what you think would be appropriate to apply the G2211 modifier.
Would you agree with my YES/NO in these scenarios below?
A) Metastatic malignancy currently on active induction chemo or immunotherapy or maintenance systemic therapy - YES
B) Metastatic malignancy, completed a period of treatment, currently on clinical/imaging surveillance - YES
C) Early stage cancer on chemotherapy or endocrine therapy - YES
D) Malignancy on targeted therapy - YES
E) MGUS - YES OR NO? - I am seeing them every 3-6 months, so this is ongoing care, but is this serious/complex? What would you do?
F) Iron deficiency anemia, has required parenteral iron a couple of times, being assessed every 6 months with labs to see if they are iron deficient and require PO/parenteral iron - YES? Or NO? If NO, if I am also commenting on their blood pressure or if they have a history of B12 deficiency that is now corrected - would this sway you toward YES?
G) Breast cancer diagnosed 6 years ago - completed 5 years of endocrine therapy - now on annual mammograms and exam and labs - YES or NO? Probably NO? But I am still seeing them long-term yearly, would this qualify for a YES?
H) History of DVT/PE, on apixaban or rivaroxaban, but only seeing them every 6 months or 1 year - YES or NO?
I) ITP patient not on treatment being followed with labs every 3 months - NO maybe?
I am having a bit of a hard time with what I perceive are grey areas in some of the scenarios above. Your opinion or a discussion on these would be quite helpful for us all, I think. Thank you.